Blau Farmacêutica S.A. (BVMF:BLAU3)
Brazil
· Delayed Price · Currency is BRL 10.06
-0.17 (-1.66%)
Apr 28, 2026, 5:07 PM GMT-3
Blau Farmacêutica Income Statement
Financials in millions BRL. Fiscal year is January - December.
Millions BRL. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,702 | 1,754 | 1,373 | 1,407 | 1,366 | Upgrade
|
| Revenue Growth (YoY) | -2.96% | 27.81% | -2.44% | 2.96% | 15.62% | Upgrade
|
| Cost of Revenue | 1,020 | 1,096 | 882.38 | 739.03 | 700.47 | Upgrade
|
| Gross Profit | 682.74 | 658.75 | 490.25 | 667.88 | 665.93 | Upgrade
|
| Selling, General & Admin | 352.99 | 313.77 | 150.28 | 213.85 | 201.77 | Upgrade
|
| Other Operating Expenses | -24.64 | 16.19 | -117.75 | 1.83 | 5.41 | Upgrade
|
| Operating Expenses | 328.35 | 329.95 | 41.97 | 215.69 | 209.31 | Upgrade
|
| Operating Income | 354.39 | 328.8 | 448.28 | 452.19 | 456.62 | Upgrade
|
| Interest Expense | -71.88 | -58.31 | -32.11 | -32.43 | -26.8 | Upgrade
|
| Interest & Investment Income | 48.07 | 46.69 | 55.8 | 70.22 | 34.95 | Upgrade
|
| Earnings From Equity Investments | - | - | 0.16 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 21.69 | -18.89 | -8.6 | -4.45 | 1.23 | Upgrade
|
| Other Non Operating Income (Expenses) | 36.21 | -6.39 | -10.3 | -16.97 | 16.46 | Upgrade
|
| EBT Excluding Unusual Items | 388.47 | 291.89 | 453.23 | 468.56 | 482.47 | Upgrade
|
| Other Unusual Items | - | - | -119 | - | - | Upgrade
|
| Pretax Income | 388.47 | 291.89 | 334.23 | 468.56 | 482.47 | Upgrade
|
| Income Tax Expense | 91.7 | 78.36 | 86.74 | 108.07 | 158.6 | Upgrade
|
| Earnings From Continuing Operations | 296.77 | 213.53 | 247.49 | 360.49 | 323.86 | Upgrade
|
| Minority Interest in Earnings | -1.82 | 3.68 | 2.32 | 2.88 | 1.36 | Upgrade
|
| Net Income | 294.96 | 217.21 | 249.81 | 363.37 | 325.22 | Upgrade
|
| Net Income to Common | 294.96 | 217.21 | 249.81 | 363.37 | 325.22 | Upgrade
|
| Net Income Growth | 35.80% | -13.05% | -31.25% | 11.73% | 27.87% | Upgrade
|
| Shares Outstanding (Basic) | 231 | 231 | 231 | 231 | 233 | Upgrade
|
| Shares Outstanding (Diluted) | 231 | 231 | 231 | 231 | 233 | Upgrade
|
| Shares Change (YoY) | - | - | -0.08% | -0.87% | 13.84% | Upgrade
|
| EPS (Basic) | 1.28 | 0.94 | 1.08 | 1.57 | 1.39 | Upgrade
|
| EPS (Diluted) | 1.28 | 0.94 | 1.08 | 1.57 | 1.39 | Upgrade
|
| EPS Growth | 35.80% | -13.05% | -31.18% | 12.69% | 12.33% | Upgrade
|
| Free Cash Flow | 28.8 | 364.53 | 71.14 | 29.24 | 5.93 | Upgrade
|
| Free Cash Flow Per Share | 0.13 | 1.58 | 0.31 | 0.13 | 0.03 | Upgrade
|
| Dividend Per Share | - | - | 0.295 | 0.495 | - | Upgrade
|
| Dividend Growth | - | - | -40.40% | - | - | Upgrade
|
| Gross Margin | 40.11% | 37.55% | 35.72% | 47.47% | 48.74% | Upgrade
|
| Operating Margin | 20.82% | 18.74% | 32.66% | 32.14% | 33.42% | Upgrade
|
| Profit Margin | 17.33% | 12.38% | 18.20% | 25.83% | 23.80% | Upgrade
|
| Free Cash Flow Margin | 1.69% | 20.78% | 5.18% | 2.08% | 0.43% | Upgrade
|
| EBITDA | 405.37 | 368.91 | 478.15 | 469.62 | 474.85 | Upgrade
|
| EBITDA Margin | 23.81% | 21.03% | 34.83% | 33.38% | 34.75% | Upgrade
|
| D&A For EBITDA | 50.98 | 40.11 | 29.87 | 17.43 | 18.22 | Upgrade
|
| EBIT | 354.39 | 328.8 | 448.28 | 452.19 | 456.62 | Upgrade
|
| EBIT Margin | 20.82% | 18.74% | 32.66% | 32.14% | 33.42% | Upgrade
|
| Effective Tax Rate | 23.61% | 26.85% | 25.95% | 23.06% | 32.87% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.